Serum Hepatocyte Growth Factor in Patients with Peripheral Arterial Occlusive Disease

Hepatocyte growth factor (HGF) is a multifunctional protein implicated in tissue regeneration, wound healing, and angiogenesis. We measured serum HGF concentrations in 37 patients with peripheral arterial occlusive disease (PAOD). Among them, 36 patients underwent arteriography. Serum HGF concentrations were also measured in 40 control subjects who remained free of vascular, liver, kidney, or lung disease. Patients with PAOD showed elevated serum HGF concentrations compared with control subjects (0.40 ± 0.02 vs. 0.19 ± 0.01 ng/mL; P < 0.001). Serum HGF concentrations were significantly higher in smokers compared with nonsmokers (0.45 ± 0.03 vs. 0.35 ± 0.02 ng/mL; P = 0.003). The serum HGF concentrations in patients with collaterals tended to be higher than those in patients without collaterals (0.43 ± 0.03 vs. 0.35 ± 0.02 ng/mL; P = 0.06). Moreover, in patients who underwent bypass surgery or angioplasty, serum HGF concentrations decreased from 0.41 ± 0.03 to 0.21 ± 0.04 ng/mL after treatment (P < 0.001). Serum HGF may be an useful marker for the diagnosis of PAOD. HGF may play an important role in angiogenesis and collateral vessel growth in PAOD.